Since the introduction of v-raf murine sarcoma viral oncogene homolog B1 (BRAF) and methyl ethyl ketone protein kinase (MEK) inhibitors, followed by immunotherapy with immune checkpoint inhibitors (ICIs), the overall survival of patients with stage III and IV melanoma has greatly improved [2]. This evidence concerns the gene BRAF and melanoma.